Proteomics analysis of Mycobacterium smegmatis subcellular fractions
Ontology highlight
ABSTRACT:
INSTRUMENT(S):
ORGANISM(S): Mycobacterium Smegmatis (strain Atcc 700084 / Mc(2)155)
SUBMITTER: 
Julien Marcoux
LAB HEAD: Julien Marcoux
PROVIDER: PXD017602 | Pride | 2020-06-17
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| F083874.dat | Other | |||
| F083875.dat | Other | |||
| F083876.dat | Other | |||
| F083878.dat | Other | |||
| F083880.dat | Other |
Items per page: 5 1 - 5 of 130 |
Similar Datasets
Project description:Proteomics analysis of pre-40S ribosomal particles.
2020-03-09 | PXD016577 | Pride
Project description:Proteomics analysis of late human pre-40S particles purified using a catalytically-inactive RIO1 as bait. Analysis of RIO1(kd)-StHA pre-40S particles composition upon RPS26 depletion with siRNA.
2021-05-12 | PXD019270 | Pride
Project description:The completion of the Plasmodium falciparum clone 3D7 genome provides a basis on which to conduct comparative proteomics studies of this human pathogen. Here, we applied a high-throughput proteomics approach to identify new potential drug and vaccine targets and to better understand the biology of this complex protozoan parasite. We characterized four stages of the parasite life cycle (sporozoites, merozoites, trophozoites and gametocytes) by multidimensional protein identification technology. Functional profiling of over 2,400 proteins agreed with the physiology of each stage. Unexpectedly, the antigenically variant proteins of var and rif genes, defined as molecules on the surface of infected erythrocytes, were also largely expressed in sporozoites. The detection of chromosomal clusters encoding co-expressed proteins suggested a potential mechanism for controlling gene expression. Keywords: ordered
2002-12-22 | E-GEOD-92 | biostudies-arrayexpress
Project description:Combined therapy with anti-BRAF plus anti-MEK is currently used as first-line treatment of patients with metastatic melanomas harboring the somatic BRAF V600E mutation. However, the main issue with targeted therapy is the acquisition of tumor cell resistance. In 70% of resistant melanoma cells, the resistant process consists in epithelial-to-mesenchymal transition (EMT). This process called phenotype switching makes melanoma cells more invasive. Its signature is characterized by MITF low, AXL high, and actin cytoskeleton reorganization through RhoA activation. In parallel of this phenotype switching phase, the resistant cells exhibit an anarchic cell proliferation due to hyper-activation of the MAP kinase pathway. We show that a majority of human melanoma overexpress discoidin domain receptor 2 (DDR2) after treatment. The same result was found in resistant cell lines presenting phenotype switching compared to the corresponding sensitive cell lines. We demonstrate that DDR2 inhibition induces a decrease in AXL expression and reduces stress fiber formation in resistant melanoma cell lines. In this phenotype switching context, we report that DDR2 control cell and tumor proliferation through the MAP kinase pathway in resistant cells in vitro and in vivo. Therefore, inhibition of DDR2 could be a new and promising strategy for countering this resistance mechanism.
2023-05-02 | PXD028292 | Pride
Project description:Background & Aims: Histone deacetylases (HDACs) are among the most common epigenetic dysregulations found in cancer, and considered as key events in tumour development and progression. Here we explored the therapeutic effects of romidepsin, a class-I HDAC inhibitor (HDACi), alone and in combination with receptor tyrosine kinase inhibitors (RTKi) in hepatocellular carcinoma (HCC). Methods: We bioinformatically evaluated class-I HDACs relevance in HCC patients through available datasets. Effects of romidepsin were assessed in HCC cell and mouse models. Molecular alterations were determined using proteomics, biochemistry, metabolic assays, immunostaining. The proteomic analysis was performed on Huh7 human HCC cell line non-treated or treated with romidepsin, cabozantinib or their combination, for 24h. Results: We report that overexpression of HDAC1 and HDAC2 occurs in HCC patients across five cohorts, and is correlated with decreased overall survival. We found that their targeting by romidepsin in HCC cell lines affects levels of several signals involved in cell cycle/survival and confers RTKi responsiveness. Mechanistically, romidepsin perturbs lipid metabolism, reduces cholesterol levels and upregulates fatty acid modulators. Furthermore, romidepsin affects the mitotic spindle machinery, leading to monopolar spindle formation, altered chromosome segregation, and cell blockage into mitosis illustrated by an accumulation of phospho-histone H3 positive HCC cells. Combined treatment of HCC cells with romidepsin plus cabozantinib (RomiCabo) switches a cytostatic effect, by romidepsin alone, into cell death by apoptosis. In vivo, RomiCabo induces regression of a subset of spontaneous preneoplastic as well as advanced lesions in the Alb-R26Met model faithfully recapitulating HCC resistance and heterogeneity. We characterize the upregulation of HR23B, a biomarker for tumour sensitivity to HDAC inhibition, and downregulation of the HCC marker AFP in RomiCabo treated Alb-R26Met tumours. Conclusions: Our findings provide the rationale of using romidepsin to exacerbate the vulnerability of HCC to RTKi for the treatment of patient subgroups.
2025-08-04 | PXD041166 | Pride
Project description:ß-catenin is a main oncogene in a large number of cancers (colorectal, liver, melanoma, uterus). Local immunosuppression induced by certain cancers remains a major problem of resistance to immunotherapies and its molecular mechanism remains poorly understood. Recently, ß-catenin mutated tumors (hepatocellular carcinoma (HCC) and melanoma) have been described as promoting immune evasion and resistance to anti-PD1 immunotherapy. Based on preliminary data obtained in HCC, we hypothesize that a defect in intercellular communication could be the cause of this immune evasion. The main objective of this project is to identify proteomic signatures of factors that can induce this immune escape in ß-catenin mutated HCC such as exosomes.
2024-07-08 | PXD043841 | Pride
Project description:FBXL6 is a E3 ubiquitin ligase that we suspected to be involved in mitochondrial functions. We have investigated the specific interactome of this E3 by transfecting HEK cells with Flagged-FBXL6, or with b-gal (control). After flag immunoprecipiation, specific interacting proteome was identified by mass spectrometry and discriminate from control IP.
2023-09-25 | PXD037248 | Pride
Project description:FBXL6 is E3 ubiquitin ligase that we suspected to be involved in mitochondrial functions. We have investigated how deletion of this E3s by CRSIPR/Cas in Hela cells affects the cellular proteome. We compared this proteome to cells treated with CRISPR Non-Targeting Control (control cells).
2023-09-25 | PXD037252 | Pride
Project description:Entosis is a process that leads to the formation of cell-in-cell structures commonly found in cancers. Here, we identified entosis in hepatocellular carcinoma and the loss of Rnd3 as an efficient inducer of this mechanism. We characterized the different stages and the molecular regulators of entosis induced after silencing of Rnd3. We demonstrated that this process is dependent on RhoA/ROCK pathway, but independent on E-cadherin. The proteomic analysis of entotic cells allowed us to identify LAMP-1 as a protein implicated not only in the degradation final stage of entosis, but also in the full mechanism. By analyzing entosis in human hepatocellular carcinoma samples, we found a relationship between the presence of entotic cells and the metastatic potential of tumors. Altogether, these data suggest the involvement of entosis in liver tumor progression and highlight a new perspective for the entosis analysis in medicine research as a novel therapeutic target.
2024-01-26 | PXD043640 | Pride
Project description:Background: Diclofenac is a non-steroidal anti-inflammatory drug frequently found in the aquatic environment. Previous studies have reported histological changes in the liver, kidney and gills of fish at concentrations similar to those measured in treated sewage effluents (~1 µg/L). Analyses or predictions of blood plasma levels in fish allow a direct comparison with human therapeutic plasma levels, and may therefore be used to indicate a risk for pharmacological effects in fish. To relate internal exposure to a pharmacological interaction we therefore investigated global hepatic gene expression together with bioconcentration to blood plasma and liver of rainbow trout (Oncorhynchus mykiss) exposed to waterborne diclofenac. Results: At the highest exposure (81.5µg/L) the fish plasma concentration reached ~88% of the human therapeutic levels (Cmax) after two weeks. Using an oligonucleotide microarray followed by quantitative PCR we found extensive effects on hepatic gene expression at this concentration, and some genes were regulated down to the lowest concentration tested (1.6 µg/L) corresponding to ~1.5% of the human Cmax. Functional analysis of differentially expressed genes revealed effects on biological processes such as inflammation and immune response, in agreement with the expected mode of action of diclofenac. In contrast to some previously reported results, the bioconcentration factor was found to be stable (4.02±0.75 for blood plasma and 2.54±0.36 for liver) regardless of the water concentration. Conclusions: Hepatic gene expression is affected in fish at blood levels similar to and below the human Cmax. This adds confidence to the use of fish blood plasma levels to predict risks for pharmacological responses in fish. The microarray results indicate similarities in the mode of action of diclofenac between humans and fish. The identified set of regulated genes may contain useful exposure biomarkers to be used in complex exposure scenarios. Juvenile rainbow trout was exposed to waterborne diclofenac at a series of different concentrations for 14 days. A flow-through system was used for eight aquaria (two per concentration), each containing 12 trouts. Nominal exposure concentrations: 1µg/L, 10 µg/L, 100 µg/L and control. Total RNA for biotinylated aRNA synthesis was extracted from the liver. Samples of aRNA from two fish from the same aquarium were pooled before the assay. In total, four biochips were analyzed corresponding to 32 microarrays. As we used two aquaria per concentration, these 32 microarrays allowed the analyses of four aRNA pools (eight fish) per aquarium, which is equal to eight pools per concentration of diclofenac.
2011-08-22 | E-GEOD-23053 | biostudies-arrayexpress